Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Looks To Bring First-In-Class Vascular Disrupting Agent To Market

This article was originally published in The Pink Sheet Daily

Executive Summary

Company will move the oncologic into Phase III in non-small cell lung cancer in 2008 under a deal with Antisoma, potentially worth more than $890 million.

You may also be interested in...



Novartis/Antisoma's ASA404 Stumbles Badly In Phase III Lung Cancer Trial

Novartis and Antisoma prematurely halted a Phase III study of ASA404 - a potentially first-in-class tumor vascular-disrupting agent - after an interim analysis showed that continuing the trial would be futile. Though lung cancer is a notorious mine field for drug development, the March 29 news still was a big surprise since a similar Phase II trial showed a significant survival benefit in patients treated with the drug

Novartis/Antisoma's ASA404 Stumbles Badly In Phase III Lung Cancer Trial

Novartis and Antisoma prematurely halted a Phase III study of ASA404 - a potentially first-in-class tumor vascular-disrupting agent - after an interim analysis showed that continuing the trial would be futile. Though lung cancer is a notorious mine field for drug development, the March 29 news still was a big surprise since a similar Phase II trial showed a significant survival benefit in patients treated with the drug

Novartis And Antisoma's ASA404 Stumbles Badly In A Phase III Lung Cancer Trial

Prospects for what was thought to be a promising first-in-class lung cancer treatment dim after a Phase III trial is halted early due to futility of improving survival.

Related Content

Topics

UsernamePublicRestriction

Register

OM006922

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel